Total Payments
$1.4M
2024 Payments
$458,973
Companies
25
Transactions
2,129
Medicare Patients
1,128
Medicare Billing
$114,767
Payment Breakdown by Category
Other$981,066 (69.2%)
Consulting$198,127 (14.0%)
Travel$189,264 (13.4%)
Food & Beverage$48,744 (3.4%)
Education$50.22 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $976,423 | 564 | 68.9% |
| Consulting Fee | $198,127 | 81 | 14.0% |
| Travel and Lodging | $189,264 | 660 | 13.4% |
| Food and Beverage | $48,744 | 817 | 3.4% |
| Honoraria | $4,643 | 5 | 0.3% |
| Education | $50.22 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $753,129 | 949 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $224,398 | 281 | $0 (2024) |
| ITI, Inc. | $142,929 | 264 | $0 (2023) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95,794 | 150 | $0 (2024) |
| Axsome Therapeutics, Inc. | $46,780 | 87 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $45,122 | 143 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $33,251 | 39 | $0 (2024) |
| Alkermes, Inc. | $18,912 | 29 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $16,919 | 69 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $9,341 | 23 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $458,973 | 739 | Teva Pharmaceuticals USA, Inc. ($208,092) |
| 2023 | $426,187 | 606 | Teva Pharmaceuticals USA, Inc. ($223,084) |
| 2022 | $343,462 | 508 | Teva Pharmaceuticals USA, Inc. ($184,232) |
| 2021 | $188,630 | 276 | Teva Pharmaceuticals USA, Inc. ($137,720) |
All Payment Transactions
2,129 individual payment records from CMS Open Payments — Page 1 of 86
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,680.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,196.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $101.84 | General |
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $28.80 | General |
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,531.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $2,126.25 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $5,062.50 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,656.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,656.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $1,220.02 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $115.43 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $130.54 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $10.68 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,680.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,380.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $60.57 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $40.37 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $35.72 | General |
| Category: Neuropsychiatry | ||||||
| 12/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: Neuropsychiatry | ||||||
| 12/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | In-kind items and services | $888.93 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,375.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $701.14 | General |
| Category: Psychiatry/Psychology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 299 | 490 | $79,375 | $38,637 |
| 2022 | 7 | 172 | 297 | $65,448 | $21,565 |
| 2021 | 5 | 297 | 427 | $57,699 | $22,365 |
| 2020 | 8 | 360 | 633 | $95,331 | $32,200 |
Total Patients
1,128
Total Services
1,847
Medicare Billing
$114,767
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 143 | 287 | $47,355 | $20,892 | 44.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 109 | 109 | $21,800 | $12,317 | 56.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 18 | 48 | $6,000 | $3,323 | 55.4% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 14 | 30 | $2,700 | $1,447 | 53.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 16 | $1,520 | $657.79 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 119 | $23,994 | $8,806 | 36.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 63 | $16,850 | $4,207 | 25.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 20 | 20 | $4,924 | $2,608 | 53.0% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Office | 2022 | 15 | 30 | $5,521 | $1,764 | 32.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 11 | 11 | $3,971 | $1,270 | 32.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 22 | $4,124 | $1,016 | 24.6% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Office | 2022 | 12 | 12 | $3,319 | $1,006 | 30.3% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 14 | 20 | $2,745 | $886.30 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 100 | $15,275 | $6,357 | 41.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 85 | 129 | $13,092 | $5,308 | 40.5% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Office | 2021 | 45 | 72 | $10,814 | $3,054 | 28.2% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Office | 2021 | 30 | 43 | $8,023 | $2,430 | 30.3% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 22 | 22 | $3,344 | $1,859 | 55.6% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Office | 2021 | 16 | 16 | $2,960 | $1,292 | 43.7% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 17 | 21 | $2,247 | $1,148 | 51.1% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 20 | 24 | $1,944 | $917.31 | 47.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 80 | 147 | $22,417 | $7,952 | 35.5% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Office | 2020 | 57 | 137 | $21,331 | $6,164 | 28.9% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Office | 2020 | 47 | 94 | $16,050 | $5,602 | 34.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 88 | 158 | $15,800 | $5,545 | 35.1% |
About Amber Hoberg, PMHNP-BC
Amber Hoberg, PMHNP-BC is a Psychiatric/Mental Health healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2010. The National Provider Identifier (NPI) number assigned to this provider is 1003122532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amber Hoberg, PMHNP-BC has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $458,973 received in 2024. These payments were reported across 2,129 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($976,423).
As a Medicare-enrolled provider, Hoberg has provided services to 1,128 Medicare beneficiaries, totaling 1,847 services with total Medicare billing of $114,767. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatric/Mental Health
- Other Specialties Psychiatric/Mental Health
- Location San Antonio, TX
- Active Since 08/21/2010
- Last Updated 07/13/2024
- Taxonomy Code 363LP0808X
- Entity Type Individual
- NPI Number 1003122532
Products in Payments
- AUSTEDO (Drug) $391,309
- CAPLYTA (Drug) $238,723
- INGREZZA (Drug) $224,174
- Austedo XR (Drug) $217,502
- UZEDY (Drug) $127,501
- Auvelity (Drug) $46,716
- NUPLAZID (Drug) $44,322
- COBENFY (Drug) $28,626
- NUEDEXTA (Drug) $14,840
- ARISTADA (Drug) $13,432
- REXULTI (Drug) $9,723
- PERSERIS (Drug) $8,494
- IGALMI (Drug) $6,248
- LYBALVI (Drug) $5,354
- ABILIFY MAINTENA (Drug) $4,842
- VRAYLAR (Drug) $401.83
- INVEGA SUSTENNA (Drug) $163.81
- Lucemyra (Drug) $133.26
- LATUDA (Drug) $67.78
- Sunosi (Drug) $63.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatric/Mental Health Doctors in San Antonio
Monique Gonzalez, Dnp, Pmhnp-Bc, DNP, PMHNP-BC
Psychiatric/Mental Health — Payments: $99,504
Psychiatric/Mental Health $99,504
Geoffrey Gonzales, Pmhnp, PMHNP
Psychiatric/Mental Health — Payments: $43,499
Psychiatric/Mental Health $43,499
Mrs. Teresa Harper, Pmhnp-Bc, PMHNP-BC
Psychiatric/Mental Health — Payments: $9,613
Psychiatric/Mental Health $9,613
Suzanne Perakathu, Pmhnp-Bc, PMHNP-BC
Psychiatric/Mental Health — Payments: $8,667
Psychiatric/Mental Health $8,667
Mrs. Nancy Daniels, Aprn,Bc, APRN,BC
Psychiatric/Mental Health — Payments: $8,529
Psychiatric/Mental Health $8,529
Christina Wei, Pmhnp, PMHNP
Psychiatric/Mental Health — Payments: $7,095
Psychiatric/Mental Health $7,095